Chronic Lyme Disease Treatment: What the Evidence Shows Beyond Antibiotics

Few topics in medicine generate as much controversy, confusion, and patient frustration as chronic Lyme disease. Patients with debilitating symptoms after Lyme infection are caught between a mainstream medical establishment that often dismisses their complaints and an alternative community that pushes treatments with limited evidence and real risks. Neither position serves patients well.

This article covers what the evidence actually shows, where the scientific debate is legitimate, and what treatment approaches have the most rational basis for the real syndrome that underlies most “chronic Lyme” presentations. For the full overview of Lyme disease management, see our Lyme disease guide.

Defining the Problem: PTLDS vs. “Chronic Lyme”

Post-treatment Lyme disease syndrome (PTLDS) is the term used by the IDSA (Infectious Diseases Society of America) to describe the subset of patients who complete standard antibiotic treatment for confirmed Lyme disease and continue to have symptoms for more than 6 months. The IDSA position is that PTLDS does not represent ongoing active infection with Borrelia burgdorferi in most cases.

“Chronic Lyme disease” is the term used by ILADS (International Lyme and Associated Diseases Society) and patient advocates, which frames the syndrome as indicating persistent active infection requiring ongoing antibiotic treatment. The evidence base for this framing is weak, and the treatment approaches it implies have been tested and found wanting in controlled trials.

These labels matter because they drive treatment decisions. Patients who receive a “chronic Lyme” framing often end up on prolonged IV antibiotic courses with meaningful risks and no demonstrated benefit. Understanding what the trials actually showed is essential.

What the Antibiotic Trials Found

Three well-designed randomized controlled trials have specifically tested prolonged antibiotic treatment in patients with persistent Lyme symptoms. The results are consistent.

Krupp 2003 (Neurology, n=55)

Krupp et al. randomized patients with PTLDS and fatigue to 28 days of IV ceftriaxone versus placebo. At the primary endpoint (6 months), the antibiotic group showed improvement in fatigue scores compared to placebo, but no improvement in cognitive functioning. The trial was stopped early by its safety monitoring board due to serious adverse events in the antibiotic group, including one case of biliary obstruction requiring surgery.

Fallon 2008 (Neurology, n=37)

Fallon et al. gave 10 weeks of IV ceftriaxone to patients with PTLDS and cognitive complaints. At 12 weeks, the antibiotic group showed cognitive improvement. But at 24 weeks, after antibiotics stopped, gains had largely disappeared, and there was no sustained benefit over placebo. Serious adverse events occurred in the antibiotic group, including a Staphylococcus aureus bacteremia from the IV line.

STOP-LD Trial 2016 (Annals of Internal Medicine, n=280)

The STOP-LD trial was the largest and most rigorous. Patients meeting PTLDS criteria were randomized to 12 weeks of doxycycline versus placebo. At all follow-up points (14 weeks, 26 weeks, 52 weeks), there were no significant differences in fatigue, pain, or cognitive measures between groups. Doxycycline provided no benefit over placebo in this population.

Taken together, these three trials show that prolonged antibiotics do not produce sustained benefit in PTLDS and carry real procedural and microbiological risks. This does not mean patients are not suffering. It means their suffering is not being driven by active bacterial replication that antibiotics can address.

What Is Actually Causing PTLDS Symptoms?

The most plausible mechanisms are post-infectious immune dysregulation and, in some cases, autoimmunity. Borrelia infection triggers a robust immune response. In some patients, this response persists after the bacteria are cleared, driven by molecular mimicry (immune cells attacking host tissue that resembles bacterial antigens), residual bacterial debris, or aberrant immune activation that becomes self-sustaining.

A 2022 study in Cell (Bhatt et al., n=79) found persistent immune dysregulation in PTLDS patients including elevated inflammatory cytokines, activated B cells, and elevated kynurenine pathway metabolites. These findings were present up to 7 years after initial infection. The immune profile was distinct from both healthy controls and currently infected patients, supporting the post-infectious dysregulation hypothesis.

A subset of patients with post-Lyme arthritis have been found to have autoantibodies to host proteins including MMP-10, a matrix metalloprotease expressed in joint tissue. In these patients, the joint inflammation continues after infection clearance because the immune system is attacking host tissue, not bacteria. Treatment with hydroxychloroquine and disease-modifying antirheumatic drugs (DMARDs) produces better outcomes than antibiotics in this autoimmune-dominant subset.

Emerging and Experimental Approaches

Low-Dose Naltrexone (LDN)

LDN (1.5-4.5mg daily) reduces neuroinflammation by modulating microglial and astrocyte activation, which is directly relevant to the central sensitization and cognitive symptoms seen in PTLDS. Given the overlap between PTLDS symptom profiles and conditions where LDN has a stronger evidence base (ME/CFS, fibromyalgia, autoimmune conditions), it has a rational mechanistic basis for trial in PTLDS patients.

Dedicated LDN trials in PTLDS do not yet exist, but patient registries and case series report meaningful improvements in fatigue, pain, and cognitive function. The excellent safety profile makes it a reasonable option for clinicians managing PTLDS who are willing to use off-label treatments.

Herbal Protocols

Zhang et al. (2020, Frontiers in Medicine) published in vitro data showing that a combination of dapsone, doxycycline, and cefuroxime, alongside certain botanical compounds, produced greater killing of Borrelia stationary-phase forms than antibiotics alone. The botanical compounds tested included cryptolepis, black walnut, sweet wormwood, cat’s claw, and Japanese knotweed. This work was entirely in vitro; no human trial of this combination has been completed, and in vitro activity does not predict in vivo clinical benefit.

Buhner’s herbal protocol (centered on Japanese knotweed/resveratrol, cat’s claw, andrographis) is widely used in the integrative Lyme community. Some herbs in this protocol have real anti-inflammatory effects that may provide symptomatic relief independent of any anti-Borrelia activity. Resveratrol, for example, has demonstrated neuroprotective and anti-inflammatory properties in multiple non-Lyme research contexts. Patients using these protocols should be aware that the evidence is mechanistic and in vitro, not clinical trial data.

Disulfiram

Disulfiram (Antabuse), typically used for alcohol use disorder, was found in 2016 in vitro research by Pothineni and Bhattacharya to have activity against Borrelia persisters, including stationary-phase forms that are not eliminated by standard antibiotics. This generated significant interest in the ILADS community.

A small retrospective case series (Liegner 2020, Antibiotics, n=8) reported improvements in some patients on disulfiram, but also documented significant neuropsychiatric adverse effects in several patients. No randomized trial has been completed. The in vitro data is interesting but far from a clinical endorsement. Disulfiram has a real risk profile and should not be used outside of monitored clinical research settings.

Ozone Therapy

Ozone therapy is used at some integrative clinics for PTLDS on the rationale that ozone has antimicrobial properties and may modulate immune function. The clinical evidence in Lyme is limited to case reports and anecdotal series. There are no randomized controlled trials. The mechanism is plausible in theory (ozone has documented effects on oxidative stress and immune signaling), but translating in vitro antimicrobial activity to clinical benefit in a complex post-infectious syndrome is a large leap that has not been validated.

Hyperbaric Oxygen Therapy (HBOT)

HBOT has been proposed for chronic Lyme on both antimicrobial grounds (Borrelia is microaerophilic and may be sensitive to hyperoxia) and neurological grounds (HBOT reduces neuroinflammation and promotes tissue repair). Animal studies have shown some promising results. Human data consists of case reports and a small uncontrolled series (Fife et al., 1996) reporting symptom improvement. No randomized trial has been completed in PTLDS. Given the evidence from long COVID brain fog research (Zilberman-Itskovich 2022), HBOT may have a rational role for the neurological component of PTLDS, but this is extrapolation, not direct evidence.

IV Vitamin C

High-dose intravenous vitamin C has been proposed based on antioxidant and immune-modulating properties. The evidence in PTLDS is anecdotal. IV vitamin C is used across integrative medicine practices for various chronic conditions, and while it is generally well-tolerated, the specific evidence in Lyme is essentially absent. The rationale is that oxidative stress and immune dysregulation are both present in PTLDS, and IV vitamin C addresses both. This is mechanistically reasonable but clinically unvalidated in this population.

Evidence Summary

What Patients Deserve to Know

The PTLDS patient population is real, their symptoms are real, and they often receive inadequate care from clinicians who dismiss them once standard antibiotic courses are complete. That is a genuine problem in medicine.

But the response to inadequate care should not be indefinite antibiotic treatment that the evidence shows does not work and carries real harms. Patients who cycle through prolonged antibiotic courses often feel temporarily better (a placebo effect that clinical trials have documented), worsen when antibiotics stop, and then attribute worsening to return of infection rather than loss of the placebo response. This cycle does not serve them.

The most productive frame is: you have a post-infectious syndrome with a real immune and neurological basis. The bacteria are almost certainly gone. The treatment target is the dysregulated immune system and its downstream effects, not an ongoing infection. With that frame, immune-modulating approaches (LDN, hydroxychloroquine for the autoimmune subset, anti-inflammatory lifestyle interventions) and symptom-management approaches (pacing, sleep optimization, pain management) become the rational treatment priorities.

If you are seeing a clinician who is only willing to prescribe more antibiotics or who dismisses all your symptoms as psychological, consider finding a physician with expertise in post-infectious syndromes, which increasingly includes long COVID specialists who are developing relevant expertise in this disease category.

Related Reading

• Arthritis Guide: Rheumatoid Arthritis and Osteoarthritis
• Brain Fog: Causes, Testing, Treatment, and When It Signals Something Deeper
• Fibromyalgia: Causes, Diagnosis, and the Complete Treatment Guide
• Hyperbaric Oxygen Therapy (HBOT): How It Works, What It Treats, and What the Evidence Shows
• Long COVID: Symptoms, Causes, Treatment, and What Regenerative Medicine Offers
• Low Dose Naltrexone (LDN): A Comprehensive Guide to Uses, Dosing, Evidence, and Side Effects